Clinical Trial Update: Study Evaluating Venlafaxine ER in Patients With Panic Disorder [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating venlafaxine extended-release for panic disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Panic Disorder

Drugs mentioned

• Venlafaxine ER (Effexor XR) (venlafaxine extended-release)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Panic Disorder | Phase 3 | Status: COMPLETED